C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data

C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the 11 most popular AI penny stocks to buy now. On February 23, Brookline increased the firm’s price target on C4 Therapeutics Inc. (NASDAQ:CCCC) from $20 to $30, while maintaining its Buy rating on the stock. The price target increase reflects growing conviction following the initiation timing of the Phase 2 cemsidomide/CFT6455 MOMENTUM trial.

Data continues to show cemsidomide’s differentiated safety and tolerability profile, supporting a clear development path for second-line and later patient populations. The firm also noted that the progress further supports expectations for the Phase 1b trial of cemsidomide in combination with elranatamab to begin in the second quarter.

On February 23, C4 Therapeutics Inc. (NASDAQ:CCCC) reported that the first patient had been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. The trial builds on the compelling anti-myeloma activity and differentiated safety profile previously observed in the Phase 1 study.

The company noted that initiating the MOMENTUM trial represents an important milestone in advancing cemsidomide as a potential foundational therapy for multiple myeloma patients seeking a safe, oral, and convenient treatment option.

C4 Therapeutics Inc. (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company that is involved in developing novel targeted protein degradation (TPD) therapies. These small-molecule degrader therapies help to cure cancer, multiple myeloma, and other fatal diseases. The company has established several strategic partnerships, including Merck KGaA, Biogen, and Betta Pharmaceuticals.

While we acknowledge the potential of CCCC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None.